Enzyme Identified as Driver of Lung Cancer Drug Resistance
Researchers found that targeting a specific enzyme may help restore lung cancer sensitivity to existing therapies.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Does new research into cancer treatment mechanisms make you more optimistic about future medical outcomes?
Scientists have identified pyruvate carboxylase as a key factor that allows KEAP1-mutant lung cancer cells to resist treatment with KRAS G12C inhibitors. This discovery could pave the way for new combination therapies to overcome drug resistance in specific tumor types.
Why it matters
The loss of KEAP1 function forces cancer cells to rely on this specific enzyme for nucleotide production, which helps them survive despite current drug interventions. Understanding this metabolic dependency offers a new target to improve the effectiveness of existing cancer treatments.
In a preclinical study using STK11 and KEAP1 co-mutant tumor models, researchers demonstrated that pyruvate carboxylase is essential for maintaining nucleotide pools during treatment. Genetic ablation of this enzyme suppressed tumor growth, though results remain preliminary.
The details
KEAP1-mutant tumors undergo a metabolic rewiring that leads to the constitutive activation of NRF2, which in turn upregulates pyruvate carboxylase. This enzyme channels glucose-derived carbon into the TCA cycle, increasing oxaloacetate availability to support aspartate synthesis. By boosting this pathway, the cancer cells effectively maintain the nucleotide pools necessary to survive and proliferate while undergoing KRAS G12C inhibitor treatment.
Timeline
October 2, 2026: Article publication date.
Health Landscape
This finding addresses the persistent hurdle of therapeutic resistance in KRAS G12C-targeted lung cancer treatment. It advances the field by shifting the focus from solely targeting oncogenic proteins to disrupting the metabolic support systems these tumors require to survive.
These findings are limited to laboratory and tumor model settings, meaning there is no immediate change to clinical care or standard treatment protocols for patients. Individuals interested in how metabolic research may affect their specific cancer care should discuss the latest clinical trial developments with their oncologist.
The takeaway
This study highlights how metabolic dependencies can become an Achilles heel for drug-resistant cancer cells. Patients and their caregivers should monitor updates on combination therapies, as understanding these specific biomarkers is central to the future of precision oncology.
Further reading
For more on the current research regarding lung malignancy management, visit Cancer.
Source note: This article includes information reported by Nature.
Live Poll
Does new research into cancer treatment mechanisms make you more optimistic about future medical outcomes?
